From science to clinical impact

Mesenchymal stromal cells (MSCs) were first described in the late 1960s and have since been intensively studied both in the laboratories and clinical trials.

MSCs have immune-modulatory, anti-inflammatory and regenerative properties. Both autologous and allogeneic MSCs have been used for the treatment of hematological, inflammatory and autoimmune diseases for the last 20 years.

The cells can be isolated from various tissues including bone marrow, adipose tissue, umbilical cord tissue and cord blood. MSCs can be induced to differentiate into osteocytes, chondrocytes and adipocytes (bone, cartilage and fat cells, respectively), but it is their immunomodulatory characteristics and potential to interact with the immune cells of the recipient that makes them unique in treatment of multiple diseases.

Mesenchymal stromal cells (MSCs) are adult multipotent stem cells capable of differentiation to multiple cell types with anti-inflammatory, immune-modulatory and regenerative characteristics, making them optimal candidates for treatment of multiple diseases.

Our bone marrow derived product is classified as an allogenic advanced therapy medicinal product (ATMP) with more than ten years of pre-clinical and clinical research. The compelling results and our highly merited research team lay a strong foundation for our clinical path ahead.

Our product – how it works

The foundation of our MSC platform stems from more than ten years of pre-clinical and clinical research by scientists in Swedish academia.

Our deep understanding of MSC biology have resulted in an ideal selection of target indications. StromaBio is now focused on taking two product candidates further to reach market authorization.

Our products are well patented, either through innovative processing or in combination with administration protocols. The outcomes of our research are compelling and lay a strong foundation for our future clinical path.

Strong IP and scientific position lay foundation for clinical path ahead